Executive Director - Clinical Pharmacology Services Quality Assurance

Fortrea completes acquisition of the Early Phase Services division from Worldwide Clinical Trials. Expands Fortrea's early clinical development network with dedicated bioanalytical capabilities, increased clinical research unit capacity and a more integrated platform for clients. Highlights * Fortrea completes acquisition of the Early Phase Services division from Worldwide Clinical Trials * Adds a 60,000-square-foot GLP-compliant bioanalytical laboratory in Austin, Texas; a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, Texas; and a biospecimen storage facility in Pflugerville, Texas * Expands Fortrea's early clinical development capacity to more than 570 beds globally and adds dedicated large and small molecule bioanalytical capabilities * Enables more integrated execution of early-phase studies by reducing operational handoffs between clinical and bioanalytical functions * Strengthens Fortrea's end-to-end clinical development platform supporting clients from first-in-human studies through Phase IV and post-approval evidence generation * Supports Fortrea's growth strategy by scaling early clinical development capabilities, increasing clinical research unit capacity and enhancing the company's ability to create long-term value for shareholders * Provides continuity of operations, study delivery and client support throughout the transition through a strategic alliance agreement between the companies DURHAM, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) - Fortrea (Nasdaq: FTRE) (the "Company"), a leading global contract research organization ("CRO"), today announced it has completed its acquisition of the Early Phase Services division from Worldwide Clinical Trials. The division consists of a Clinical Research Unit ("CRU") and Bioanalytical Laboratory operations, in an all-cash transaction valued at approximately $45 million. The acquisition strengthens Fortrea's end-to-end clinical development platform by adding a 200-bed Good Clinical Practice-compliant CRU in San Antonio, Texas; a 60,000-square-foot Good Laboratory Practice-compliant bioanalytical laboratory in Austin, Texas; and a biospecimen storage facility in Pflugerville, Texas. Together, these assets expand Fortrea's early-phase capacity to more than 570 beds globally and add in-house large and small molecule bioanalytical capabilities to support clients from first-in-human studies through proof-of-concept and later-stage development. "Completing this acquisition further strengthens our integrated, scalable and scientifically differentiated clinical development platform," said Anshul Thakral, CEO of Fortrea. "This transaction demonstrates tangible progress in Fortrea's return to growth as we invest in our ability to win new opportunities and create lasting value for clients. By bringing together complementary clinical pharmacology and bioanalytical capabilities, we expect to expand the speed, flexibility and talent we can offer clients as they advance increasingly complex development programs. We are pleased to welcome the Early Phase Services team to Fortrea and look forward to delivering a seamless experience for clients, volunteers and the patients we ultimately serve." "With this investment, Fortrea adds capability and capacity in its commitment to help clients design and execute early development programs with greater speed, scientific rigor and operational connectivity," said Scott Dove, Ph.D., president, Clinical Pharmacology Services at Fortrea. "The addition of dedicated bioanalytical capabilities and expanded CRU capacity gives our teams more ways to support both simple and complex studies, streamline execution and generate high-quality data that inform development decisions." The addition of these capabilities complements Fortrea's existing Clinical Pharmacology Services business and broadens its North American CRU footprint. The combined platform is designed to reduce operational handoffs between clinical and bioanalytical functions, improve turnaround times and provide clients with greater flexibility for complex and larger participant studies, broader access to distinct volunteer populations and expanded bedspace capacity across Fortrea's early development network. Fortrea and Worldwide Clinical Trials have also entered into agreements intended to support continuity for clients, employees and ongoing programs. Both organizations remain focused on maintaining project momentum and providing a seamless transition for employees, clients and volunteers. The acquired Early Phase Services operations are now part of Fortrea's Clinical Pharmacology Services business unit. Advisors Barclays served as financial advisor to Fortrea, and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. served as its legal counsel. About Fortrea Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. Asianet Pakistan partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Its talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow Asianet Pakistan on LinkedIn, X and Bluesky. Cautionary Statement Regarding Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the anticipated benefits of the transaction, including future financial and operating performance, and the anticipated timing for completing the transaction. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "guidance," "expect," "assume," "anticipate," "intend," "plan," "forecast," "believe," "seek," "see," "will," "would," "target," similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results could differ materially from these forward looking statements due to a number of factors, including, but not limited to: the parties' ability to meet expectations regarding the accounting and tax treatments of the proposed transaction; the anticipated benefits of the acquisition may not be realized, or may be realized more slowly or to a lesser extent than expected, difficulties, delays, costs or disruptions associated with integrating the acquired business, operations, employees, systems and processes into the Company, the ability to retain existing customers and business relationships of the acquired operations and win new business following the acquisition, the ability to retain and integrate key employees of the acquired business, the parties' ability to perform their respective obligations under transition services and other agreements, unanticipated liabilities, expenses or adverse effects associated with the acquired business, the ability to maintain applicable regulatory, quality and accreditation requirements for the acquired sites, and other factors described from time to time in documents that the Company files with the SEC. For a further discussion of the risks relating to the Company's business, see the "Risk Factors" Section of the Company's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (the "SEC"), as such factors may be amended or updated from time to time in the Company's subsequent periodic and other filings with the SEC, which are accessible on the SEC's website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included or incorporated by reference in this report and in the Company's filings with the SEC. All forward-looking statements are made only as of the date of this report and the Company does not undertake any obligation, other than as may be required by law, to update or revise any forward-looking statements to reflect future events or developments. Fortrea Contacts Galen Wilson (Media) - 703-298-0802, [email protected] Kate Dillon (Media) - 646-818-9115, [email protected] Tracy Krumme (Investors) - 984-385-6707, [email protected] GlobeNewswire Distribution ID 9848525 October 17, 2026 Islamabad:Most parts of the country are expected to experience dry weather over the next twelve hours. According to Radio Pakistan, the northern areas may see partly cloudy skies, with cold conditions anticipated during the morning and night. October 17, 2026 October 16, 2026

Fortrea to participate in September investor conferences. MWN-AI** Summary. Fortrea (Nasdaq: FTRE), a prominent global contract research organization (CRO), has announced its upcoming participation in several key investor conferences in September 2026. Leading this initiative are CEO Anshul Thakral, CFO Jason Knoblauch, and Senior Vice President of Investor Relations Tracy Krumme. The conferences include the Baird 2026 Global Healthcare Conference and Deutsche Bank 2026 Healthcare Summit in New York City, as well as the RBC Pharma Services and Life Science Tools Virtual Conference. On September 15, Fortrea will participate in a fireside chat format at the Baird conference, alongside individual and group meetings, from 2:00 to 2:30 PM EDT. A live webcast of this session will be made available for later access via the Events section of Fortrea's Investor Relations website. The following day, Fortrea will engage in one-on-one and group meetings during the Deutsche Bank summit. Additionally, the company will be involved in similar meeting formats at the RBC virtual conference on September 22. Fortrea stands out as a global leader in providing comprehensive clinical development solutions for the life sciences sector, collaborating with both emerging and established biopharmaceutical, biotechnology, and medical device companies. The organization prides itself on its extensive experience, encompassing over three decades across more than 20 therapeutic areas, and is committed to advancing healthcare innovation that accelerates the delivery of transformative therapies to patients. With a talented workforce of professionals operating in 100 countries, Fortrea is well-equipped to provide agile solutions tailored to global clients. Interested investors and stakeholders can learn more about Fortrea's initiatives and drug development approach by visiting their website and following their updates on social media platforms. MWN-AI** Analysis. As Fortrea (Nasdaq: FTRE) prepares to participate in significant investor conferences throughout September 2026, keen investors should closely monitor the company's developments and performance metrics. With CEO Anshul Thakral and CFO Jason Knoblauch set to engage with investors at the Baird 2026 Global Healthcare Conference and the Deutsche Bank 2026 Healthcare Summit, there's a substantial opportunity for insights into Fortrea's strategic initiatives and operational performance. Fortrea stands out in the contract research organization (CRO) sector, focusing on delivering clinical development solutions to both emerging biopharmaceuticals and established medical firms. The company prides itself on leveraging a rich 30-year history across more than 20 therapeutic areas, indicating robust expertise that investors could view favorably. Additionally, their expansive network of clinical trial sites in over 100 countries ensures comprehensive and agile solutions for clients, positioning Fortrea well amid increasing demand for efficient drug development services. Investors should consider the implications of Fortrea's participation in September conferences for future stock performance. A fireside chat format can often lead to candid communications about the company's pipeline, strategic vision, and market positioning, all of which are key factors influencing investor sentiment. The company's ability to articulate growth prospects and address investor inquiries can potentially lead to increased market confidence. Furthermore, with Fortrea's solutions catering to critical sectors such as biopharmaceuticals and medical devices, the ongoing industry shift towards precision medicine and accelerated drug approvals may provide additional tailwind for Fortrea's growth. Hence, investors might find it prudent to engage with the company's updates and consider investing in FTRE to capitalize on potential upside from upcoming innovations and developments in the healthcare landscape. Engaging with management at these conferences could also yield valuable insights, making outreach critical for investors looking to deepen their understanding of Fortrea's market trajectory. **MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release. September 10, 2026 08:58:16 am DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) - Fortrea (Nasdaq: FTRE), a leading global contract research organization ("CRO"), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations, Tracy Krumme will participate in the following conferences in September: Baird 2026 Global Healthcare Conference (NYC) Date: Tuesday, September 15, 2026 Format: Fireside Chat & 1x1 and Group Meetings Time: 2:00 -2:30 PM EDT Webcast: FTRE Baird Webcast Deutsche Bank 2026 Healthcare Summit (NYC) Date: Wednesday, September 16, 2026 Format: 1x1 and Group Meetings RBC Pharma Services and Life Science Tools Virtual Conference Date: Tuesday, September 22, 2026 Format: 1x1 and Group Meetings The live webcast and replay of the Baird fireside chat will be accessible through the "Events" section of Fortrea's Investor Relations website. Investors interested in meeting with management should contact their banking representatives. About Fortrea Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. Market Wire News partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Its talented and diverse team working in 100 countries is scaled to deliver focused and agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow Market Wire News on LinkedIn, X and Bluesky. Fortrea Contacts Tracy Krumme (Investors) - 984-385-6707, [email protected] Sue Zaranek (Media) - 919-943-5422, [email protected] Kate Dillon (Media) - 646-818-9115, [email protected] FAQ**. What key strategies will Fortrea Holdings Inc. (FTRE) discuss during the Baird 2026 Global Healthcare Conference to showcase their leadership in clinical development solutions? I currently do not have access to specific details about Fortrea Holdings Inc.'s strategies for the Baird 2026 Global Healthcare Conference. Please consult official company announcements or industry news for the latest information. How does Fortrea Holdings Inc. (FTRE) plan to leverage its extensive experience across therapeutic areas during the upcoming Deutsche Bank 20Healthcare Summit? Fortrea Holdings Inc. plans to leverage its extensive experience across therapeutic areas at the Deutsche Bank 2026 Healthcare Summit by showcasing innovative strategies and partnerships that enhance their portfolio and address evolving healthcare needs. What insights does Fortrea Holdings Inc. (FTRE) hope to share with investors at the RBC Pharma Services and Life Science Tools Virtual Conference regarding drug development innovation? Fortrea Holdings Inc. (FTRE) aims to share insights on groundbreaking advancements in drug development and innovative strategies that enhance efficiency and efficacy, positioning their pipeline for growth and competitiveness in the pharmaceutical industry. How is Fortrea Holdings Inc. (FTRE) addressing emerging trends in the biopharmaceutical industry while participating in these September conferences? Fortrea Holdings Inc. (FTRE) is actively engaging at September conferences to showcase its innovative therapies and align with industry trends such as personalized medicine and digital health solutions, highlighting its commitment to advancing biopharmaceutical development. **MWN-AI FAQ is based on asking OpenAI questions about Fortrea Holdings Inc. (NASDAQ: FTRE).